Drugmaker offers $1 alternative to medicine that soared 5,000% by ‘most-hated man in America’

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

NEW YORK — A San Diego-based pharmaceutical company says it will offer a low-cost alternative to Daraprim, a drug used by cancer and AIDS patients that recently skyrocketed from $13.50 to $750 a pill.

Imprimis Pharmaceuticals says the substitute drug will be priced as low as $99 for a 100-capsule bottle.

Daraprim is produced by Turing Pharmaceuticals, which came under intense fire in recent weeks after chief executive Martin Shkreli raised the price of the drug by 5,000%.

Imprimis said its substitute drug is a customized formulation that can be used to treat toxoplasmosis, the ailment that AIDS patients previously relied on Daraprim to control.

“While we respect Turing’s right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim, for patients, physicians, insurance companies and pharmacy benefit managers to consider,” Imprimis CEO Mark Baum said in a statement.

In September, Turing’s price increase caught the eye of presidential candidate Hillary Clinton, who tweeted that she wanted to put an end to drug “price gouging.”

On Monday, Clinton wrote to the Food and Drug Administration and Federal Trade Commission asking that they look at Turing Pharmaceutical’s pricing of Daraprim.

Clinton also asked the FDA to allow importation of low-price versions of the drug from the U.K. and Canada.

“Patients who rely on this treatment should not have their health and lives put at risk because of an unnecessary anti-competitive market, and the FDA should act through all of its available authorities to remedy this situation as soon as feasible,” she wrote in the FDA letter, which was first reported by Reuters.

Trademark and Copyright 2021 Cable News Network, Inc., a Time Warner Company. All rights reserved.

continue reading override